v3.24.3
Subsequent Events (Details)
9 Months Ended
Oct. 22, 2024
USD ($)
Intallment
VotingRights
$ / shares
shares
Sep. 30, 2024
shares
Oct. 15, 2025
$ / shares
Oct. 20, 2024
shares
Dec. 31, 2023
shares
Feb. 22, 2021
shares
Acquisition of Opus Genetics [Abstract]            
Common stock, shares outstanding (in shares)   26,198,444     23,977,491  
Preferred stock, shares outstanding (in shares)   0     0  
Dr. Bennett [Member]            
Acquisition of Opus Genetics [Abstract]            
Consultation services receivable period   1 year        
Dr. Yerxa [Member]            
Acquisition of Opus Genetics [Abstract]            
Consultation services receivable period   3 years        
Employment agreement term   1 year        
Employment termination period   3 months        
Employment termination multiplier 0.5          
Inducement Plan [Member]            
Acquisition of Opus Genetics [Abstract]            
Common stock reserved for issuance (in shares)           325,258
Subsequent Event [Member]            
Acquisition of Opus Genetics [Abstract]            
Common stock, shares outstanding (in shares) 31,435,507          
Preferred stock, shares outstanding (in shares) 14,145.374          
Subsequent Event [Member] | Dr. Yerxa [Member]            
Acquisition of Opus Genetics [Abstract]            
Annual base salary | $ $ 425,000          
Percentage of annual bonus 35.00%          
Payment for consultation services | $ $ 400,000          
Subsequent Event [Member] | Restricted Stock Unit [Member] | Dr. Bennett [Member]            
Acquisition of Opus Genetics [Abstract]            
Awards granted (in shares) 100,000          
Subsequent Event [Member] | Restricted Stock Unit [Member] | Dr. Yerxa [Member]            
Acquisition of Opus Genetics [Abstract]            
Number of equal installments for vesting | Intallment 4          
Vesting period 4 years          
Subsequent Event [Member] | Inducement Plan [Member]            
Acquisition of Opus Genetics [Abstract]            
Common stock reserved for issuance (in shares)       2,625,258    
Subsequent Event [Member] | Inducement Plan [Member] | Restricted Stock Unit [Member] | Dr. Yerxa [Member]            
Acquisition of Opus Genetics [Abstract]            
Awards granted (in shares) 332,800          
Subsequent Event [Member] | Series A Preferred Stock [Member]            
Acquisition of Opus Genetics [Abstract]            
Preferred stock, voting rights | VotingRights 0          
Subsequent Event [Member] | Series A Preferred Stock [Member] | Q3-2025 Dividend [Member]            
Acquisition of Opus Genetics [Abstract]            
Dividend payment date Oct. 15, 2025          
Subsequent Event [Member] | Series A Preferred Stock [Member] | Scenario, Plan [Member] | Q3-2025 Dividend [Member]            
Acquisition of Opus Genetics [Abstract]            
Cumulative dividends payable (in dollars per share) | $ / shares     $ 26      
Cash dividend payable (in dollars per share) | $ / shares     $ 15.26      
Subsequent Event [Member] | Common Stock [Member] | Dr. Yerxa [Member]            
Acquisition of Opus Genetics [Abstract]            
Maximum percentage of salary to be paid in shares 50.00%          
Subsequent Event [Member] | Opus Genetics Inc [Member] | Series A Preferred Stock [Member]            
Acquisition of Opus Genetics [Abstract]            
Shares issued (in shares) 14,145.374          
Shares issued, price per share (in dollars per share) | $ / shares $ 0.0001          
Number of shares issued upon conversion (in shares) 1,000          
Subsequent Event [Member] | Opus Genetics Inc [Member] | Common Stock [Member]            
Acquisition of Opus Genetics [Abstract]            
Shares issued (in shares) 5,237,063          
Shares issued, price per share (in dollars per share) | $ / shares $ 0.0001